Home / Market News / $NRXS

$NRXS news and market catalysts

The 9 most recent market catalysts affecting $NRXS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 2 high impact 6 bullish 1 bearish Healthcare Technology
Nov 9, 2026 Corporate Catalyst Bullish Impact 85
NeurAxis Reports Record Third Quarter 2026 Financial Results
NeurAxis announced record third-quarter 2026 financial results, with revenue surging 150% to $2.0 million, primarily driven by a 92% increase in unit deliveries following the imple…
Oct 27, 2026 Corporate Catalyst Neutral Impact 55
NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
NeurAxis, Inc. is informing the market about its upcoming third-quarter 2026 earnings release and subsequent conference call. This is a standard corporate communication, setting th…
Oct 15, 2026 Corporate Catalyst Bullish Impact 75
NeurAxis shares are trading higher. The company announced new insurance coverage for its IB-Stim PENFS therapy, expanding access to ~26 million health plan members.
This headline represents a significant corporate catalyst for NeurAxis (NRXS). Expanded insurance coverage for its IB-Stim PENFS therapy directly translates to a larger addressable…
Oct 15, 2026 Corporate Catalyst Neutral Impact 75
NeurAxis Announces Its Medical Policy Coverage Now Serves Over 26M Medical Plan Members
NeurAxis announced that a major national health insurer has approved medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy. This new cover…
Sep 16, 2026 Corporate Catalyst Bullish Impact 85
NeurAxis shares are trading higher. The company announced new medical policy coverage from a national health insurer for Percutaneous Electrical Nerve Field Stimulation, spanning multiple states and covering ~18 million members.
The headline indicates a major positive catalyst for NeurAxis (NRXS). New medical policy coverage from a national insurer for their PENFS technology, spanning multiple states and c…
Sep 16, 2026 Corporate Catalyst Bullish Impact 75
NeurAxis Announces New Medical Policy Coverage For PENFS From Unnamed National Health Insurer
The new medical policy coverage for PENFS from a national health insurer is a significant positive catalyst for NeurAxis (NRXS). Increased insurance coverage directly translates to…
Aug 11, 2026 Corporate Catalyst Bearish Impact 75
Neuraxis shares are trading lower after the company reported mixed Q2 financial results.
The mixed Q2 financial results for Neuraxis (NRXS) are a significant corporate catalyst, directly impacting its share price negatively. Investors are likely reacting to unmet expec…
Aug 11, 2026 Corporate Catalyst Bullish Impact 75
Neuraxis Q2 EPS $(0.19) Beats $(0.32) Estimate, Sales $1.929M Miss $2.000M Estimate
Neuraxis (NRXS) released its Q2 earnings, showing a mixed performance. The company successfully narrowed its losses, beating analyst EPS estimates by a significant margin, which is…
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
NeurAxis Announces Additional Medical Policy Coverage For PENFS Representing Over 500,000 Covered Lives, Expanding IB-Stim Access In Mid-Atlantic Region
The additional medical policy coverage for NeurAxis's PENFS (IB-Stim) device is a direct positive catalyst for the company. Expanding access to over 500,000 covered lives in the Mi…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.